Updating results

120 results for metastatic breast cancer Sort: Relevance | Date

Gemcitabine for the treatment of metastatic breast cancer (TA116)

Evidence-based recommendations on gemcitabine (Gemzar) for treating metastatic breast cancer

Technology appraisal guidance Published January 2007

Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)

Evidence-based recommendations on fulvestrant (Faslodex) for treating locally advanced or metastatic breast cancer

Technology appraisal guidance Published December 2011

Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

Evidence-based recommendations on bevacizumab (Avastin) in combination with capecitabine for the first-line treatment of metastatic breast cancer

Technology appraisal guidance Published August 2012

Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

Evidence-based recommendations on bevacizumab (Avastin) in combination with a taxane for the first-line treatment of metastatic breast cancer

Technology appraisal guidance Published February 2011

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy

Technology appraisal guidance Published December 2016

Advanced breast cancer

Everything NICE has said on diagnosing and treating advanced breast cancer in an interactive flowchart

NICE Pathway Published May 2011 Last updated March 2018

Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course

Technology appraisal guidance Published March 2018

Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA34)

Evidence-based recommendations on the use of trastuzumab (Herceptin) for the treatment of advanced breast cancer

Technology appraisal guidance Published March 2002

Early and locally advanced breast cancer

Everything NICE has said on diagnosing and treating early and locally advanced breast cancer in an interactive flowchart

NICE Pathway Published May 2011 Last updated December 2018

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy

Technology appraisal guidance Published December 2016

Early and locally advanced breast cancer: diagnosis and management (NG101)

This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

NICE guideline Published July 2018

Advanced breast cancer: diagnosis and treatment (CG81)

This guideline covers care and support for people with advanced (stage 4) breast cancer. It aims to help them and their healthcare professionals make shared decisions about tests and treatments to improve outcomes and quality of life.

Clinical guideline Published February 2009 Last updated August 2017

Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone receptor-positive, HER2-negative, locally advanced or

Technology appraisal guidance Published December 2017

Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)

Evidence-based recommendations on fulvestrant (Faslodex) for untreated locally advanced or metastatic (secondary) oestrogen-receptor positive breast cancer in

Technology appraisal guidance Published January 2018

Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)

Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor

Technology appraisal guidance Published December 2017

Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive, locally recurrent or metastatic (secondary) breast cancer in adults

Technology appraisal guidance Published March 2018

Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for treating advanced HER2-positive breast cancer that has been treated before

Technology appraisal guidance Published July 2017 Last updated November 2017

Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]

In development [GID-TA10342] Expected publication date: 01 July 2020

Technology appraisal guidance In development

Breast cancer (locally advanced, metastatic) - eribulin (after chemotherapy) [ID964]

In development [GID-TA10030] Expected publication date: 21 December 2016

Technology appraisal guidance In development

ESNM13: Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab

Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

Evidence summary Published March 2013

Breast cancer (QS12)

This quality standard covers the care of people with breast cancer after they have been referred to a specialist team. It includes the management of early (ductal carcinoma in situ and invasive), locally advanced and advanced breast cancer; recurrent breast cancer; and familial breast cancer. It describes high-quality care in priority areas for improvement.

Quality standard Published September 2011 Last updated June 2016

Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours

Technology appraisal guidance Published October 2012

Talazoparib for treating BRCA 1 or 2 mutated advanced breast cancer after prior chemotherapy (ID1342)

In development [GID-TA10366] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

In development [GID-TA10295] Expected publication date: 05 August 2020

Technology appraisal guidance In development

Atezolizumab for untreated, locally advanced or metastatic, triple negative, PD-L1 positive breast cancer [ID1522]

In development [GID-TA10433] Expected publication date: 20 November 2019

Technology appraisal guidance In development

Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)

Evidence-based recommendations on trastuzumab (Herceptin) for treating adenocarcinoma (HER2-positive metastatic gastric cancer/stomach cancer)

Technology appraisal guidance Published November 2010

Block scoping reports

NICE block scoping reports

Published January 2019

Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)

This guideline covers diagnosing and managing secondary cancers in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition when this cannot be found.

Clinical guideline Published July 2010

ESUOM21: Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment

Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..

Evidence summary Published October 2013

Static list

NICE technology appraisal guidance static list

Published January 2018

Metastatic malignant disease of unknown primary origin

Everything NICE has said on diagnosing and managing metastatic malignant disease of unknown primary origin in an interactive flowchart

NICE Pathway Published January 2013 Last updated July 2018

Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)

Evidence-based recommendations on topotecan (Hycamtin) for treating recurrent stage IVB (stage 4B) cervical cancer (cancer of the cervix)

Technology appraisal guidance Published October 2009

Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164)

This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).

Clinical guideline Published June 2013 Last updated March 2017

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive breast cancer in adults

Technology appraisal guidance Published December 2016

Neutropenic sepsis: prevention and management in people with cancer (CG151)

This guideline covers preventing, identifying and managing neutropenic sepsis in children, young people and adults receiving treatment for cancer in the community and in secondary and tertiary care. It aims to reduce the risk of infection in people with neutropenia (low number of white blood cells) who are receiving anticancer treatment and improve management of neutropenic sepsis.

Clinical guideline Published September 2012

MIB120: Caris Molecular Intelligence for guiding cancer treatment

Advice on the use of Caris Molecular Intelligence (CMI; solid tumour biomarker analysis service) for guiding cancer treatment to aid local decision-making

Medtech innovation briefing Published September 2017

Metastatic spinal cord compression in adults: risk assessment, diagnosis and management (CG75)

This guideline covers detecting and managing metastatic spinal cord compression in adults with cancer that has spread to the spine. It aims to improve quality of life by promoting early detection and management, and reducing spinal cord damage and disability.

Clinical guideline Published November 2008

Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]

In development [GID-TAG411] Expected publication date: TBC

Technology appraisal guidance In development

Colorectal cancer: diagnosis and management (CG131)

This guideline covers diagnosing and managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through early diagnosis and staging, management of local disease according to risk of recurrence (high, moderate, low) and management of secondary tumours (metastatic disease).

Clinical guideline Published November 2011 Last updated December 2014

Menopause: diagnosis and management (NG23)

This guideline covers the diagnosis and management of menopause, including in women who have premature ovarian insufficiency. The guideline aims to improve the consistency of support and information provided to women in menopause.

NICE guideline Published November 2015

Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision (IPG268)

Evidence-based recommendations on brachytherapy as the only type of adjuvant radiotherapy for breast cancer after local excision

Interventional procedures guidance Published July 2008

Laparoscopic mobilisation of the greater omentum for breast reconstruction (IPG253)

Evidence-based recommendations on laparoscopic mobilisation of the greater omentum (keyhole surgery) for breast reconstruction

Interventional procedures guidance Published February 2008

Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)

Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery for adults with early breast cancer

Technology appraisal guidance Published January 2018

Prostate cancer: diagnosis and management (CG175)

This guideline covers diagnosing and managing prostate cancer in secondary care. It offers information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It includes recommendations on follow-up in primary care for men with diagnosed prostate cancer.

Clinical guideline Published January 2014

Microwave ablation for treating primary lung cancer and metastases in the lung (IPG469)

Evidence-based recommendations on microwave ablation for treating primary lung cancer and metastases in the lung

Interventional procedures guidance Published November 2013

Metastatic spinal cord compression

Everything NICE has said on detecting and managing metastatic spinal cord compression in adults with cancer in an interactive flowchart

NICE Pathway Published January 2012 Last updated February 2019